Exelixis
EXEL
$51.86
Share price
0.59%
Change (1 day)
60.20%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Revenue for Exelixis (EXEL)
Revenue in 2024 (TTM): C$2.99 Billion
According to Exelixis's latest financial reports the company's current revenue (TTM 
) is C$3.00 Billion. an increase over the revenue in the year 2023 that were of C$2.42 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Exelixis from 2000 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | C$3.11 B | 28.2% |
| 2023 | C$2.42 B | 11.04% |
| 2022 | C$2.18 B | 19.54% |
| 2021 | C$1.82 B | 45.24% |
| 2020 | C$1.25 B | -0.38% |
| 2019 | C$1.26 B | 8.67% |
| 2018 | C$1.16 B | 104.45% |
| 2017 | C$0.56 B | 121.11% |
| 2016 | C$0.25 B | 398.95% |
| 2015 | C$51.56 M | 76.95% |
| 2014 | C$29.14 M | -12.65% |
| 2013 | C$33.35 M | -29.3% |
| 2012 | C$47.18 M | -83.98% |
| 2011 | C$0.29 B | 59.28% |
| 2010 | C$0.18 B | 15.84% |
| 2009 | C$0.15 B | 11.43% |
| 2008 | C$0.14 B | 26.6% |
| 2007 | C$0.11 B | -1.47% |
| 2006 | C$0.11 B | 29.9% |
| 2005 | C$88.43 M | 39.3% |
| 2004 | C$63.48 M | -5.04% |
| 2003 | C$66.85 M | -4.49% |
| 2002 | C$70 M | 7.16% |
| 2001 | C$65.32 M | 76.11% |
| 2000 | C$37.09 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | C$55.66 B | 1,752.75% | 🇬🇧 UK |
 | C$66.44 B | 2,111.48% | 🇫🇷 France |
 | C$88.89 B | 2,858.82% | 🇺🇸 USA |
 | C$66.91 B | 2,127.14% | 🇺🇸 USA |
 | C$46.30 B | 1,441.20% | 🇺🇸 USA |
 | C$123.05 B | 3,995.59% | 🇺🇸 USA |
 | C$88.14 B | 2,833.83% | 🇺🇸 USA |
 | C$15.11 M | -99.50% | 🇺🇸 USA |
 | C$0.13 B | -95.65% | 🇺🇸 USA |